AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01591265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of upper and lower FPM teeth
Description: Extraction of upper and lower FPM teeth
Study NCT01591265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of lower FPM tooth
Description: Extraction of lower FPM tooth only
Study NCT01977898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
Study NCT01977898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
Study NCT01709552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Intervention
Description: Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
Study NCT01709552 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
Study NCT01405404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training and childcare discount
Description: 12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
Study NCT01405404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: 12-session group on parenting skills and child behavior management
Study NCT02301000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intestinal microbiota therapy
Description: 60 ml of ACHIM suspension will be administered through a rectal tube
Study NCT02301000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Peroral metronidazole 400 mg t.i.d. for ten days
Study NCT03290092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib (GDC0032)
Description: The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
Study NCT03290092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib (GDC0032)
Description: The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
Study NCT03128359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given IV
Study NCT02567357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual Scheduling
Description: Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
Study NCT02567357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: signalling change
Description: Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
Study NCT03128359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT03128359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC HCT
Study NCT00425113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Study NCT00425113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Study NCT00425113 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Draw
Study NCT00425113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Study NCT00425113 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CT Scan
Study NCT03128359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03128359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT03128359 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT00425113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Study NCT00425113 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PET Scan
Study NCT02126670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACT01
Study NCT02126670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT01
Study NCT02126670 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACT01
Study NCT02126670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comp01
Study NCT02126670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comp02
Study NCT02126670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comp03
Study NCT02126670 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Comp04
Study NCT03620253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Study NCT01123148 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Using a BCI to control wheelchair tilt
Description: Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
Study NCT03460652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP415 oral capsule
Description: Once-daily oral dose
Study NCT03620253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Study NCT01781377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROPOFOL
Description: PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
Study NCT03256409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence mold and yeast and mesophyll aerobe
Description: Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
Study NCT03256409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface Roughness (Ra)
Description: The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
Study NCT01781377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METOCLOPRAMIDE
Description: METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
Study NCT01781377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: SALINE INFUSION
Study NCT00720694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duolith SD1
Study NCT02904525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 Tesla MRI, no contrast agent
Description: Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
Study NCT01934933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celebrex
Study NCT01934933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Study NCT00720694 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Duolith SD1
Study NCT04645992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active TENS
Description: study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
Study NCT04645992 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TENS
Description: control group will be treated with the same protocol as the study group but with the TENS unit is off .
Study NCT00535769 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electronic + no text message
Description: Electronic monitor is attached but no text-messages are sent through cellular phones
Study NCT00535769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic monitor + text messages
Description: Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
Study NCT02988544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artificial shrinkage
Description: Artificial shrinkage of blastocyst
Study NCT01934933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel plus Celebrex
Study NCT04718584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)
Description: All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
Study NCT03009240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03009240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01559415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal replacement diet using Modifast
Description: modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
Study NCT01559415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal diet combined with Modifast diet
Description: Combination of modifast and regular diet (1250 kcal/d) for 3 months
Study NCT01232439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid receptor kappa antagonist
Description: Starting dose of 2 mg, administered orally, once.~The potential dose range for this study is 0.2 mg to 30 mg
Study NCT03009240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study NCT03009240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01367314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVC-422
Description: Dermal Gel applied 3 times per day for 7 days
Study NCT00003595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003595 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study NCT02453698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
Study NCT02453698 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose Placebo
Study NCT00003595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Study NCT01269632 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling, specific biological exams and biobank and self administered questionnaires
Description: HIV INFECTION at inclusion and annually up to 06 years follow-up~1. clinical and therapeutic evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~1. clinical evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT02407743 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surgical patients' clinical progression
Description: Study the dynamic nature of pain
Study NCT02407743 — intervention group
Intervention type: GENETIC
Intervention: Genetic markers
Description: Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
Study NCT00670566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irbesartan/hydrochlorothiazide
Description: 50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
Study NCT03417310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H joystick
Description: A joystick that corrects lateral displacement and angulation for multi-direction reduction
Study NCT03417310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Common reduction methods
Description: Manual reduction methods without the assistance of any devices
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT01146613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 0.5mg capsules x 2, 2x a day for 12 weeks
Study NCT01146613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical matched placebo x 2, 2xday, 13 weeks
Study NCT02543853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: direct trocar entry
Description: direct trocar entry to provide pneumoperitoneum
Study NCT02543853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: veres needle entry
Description: veres needle entry to provide pneumoperitoneum
Study NCT01004536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone gel
Description: twice daily application onto designated half of cesarean section wound for 12 weeks
Study NCT00003595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT01004536 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no treatment
Description: left untreated during the study period
Study NCT00104988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 75 mg/m\^2/day PO daily for 6 weeks followed by a 2-week break
Study NCT00104988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 200 mg/day PO daily
Study NCT00579423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Description: * Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~* Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~* Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient.
Study NCT03439046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
Study NCT03439046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
Study NCT03439046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
Study NCT03439046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
Study NCT03046446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Single intra-articular injection
Study NCT03374358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
Study NCT00305448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 intramuscular injection
Study NCT00305448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular injection
Study NCT00417768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
Study NCT00417768 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
Study NCT06268002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vernonia cinerea
Description: Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
Study NCT02830243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.